Search

Displaying results 1251 - 1260 of 10000 in total
  1. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

  2. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

  3. Drug

    Hydrogen fluoride

    go.drugbank.com/drugs/DB11072
    ApprovedInvestigational

    Hydrogen fluoride (Hydrofluoric acid) is a weak acid that is a precursor to almost all fluorine compounds, including pharmaceuticals such as [DB00472] (Prozac). … It is used as a chemical reagent in several industrial processes such as oil refinery. It is also used as etchant, cleaning agent, and a reagent to dissolve oxides and silicates.

    Mixtures: All Solutions Acidulated Phosphate Fluoride Foam
  4. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. … The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime.

    Mixtures: Lypholyte Multi-electrolyte Conc Inj, PERİFERAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ, 500 ML SETLİCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjSynonyms: copper(II) chloride
  6. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.

  7. Drug

    Zolpidem

    go.drugbank.com/drugs/DB00425
    ApprovedInvestigational

    This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. … It is aimed for use in patients with difficulties initiating sleep.

    Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
  8. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy

  9. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    [A32041] It was developed by MCPRF and FDA first approved in September 2012. … Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.

  10. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]